Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI)

1.04
Delayed Data
As of 3:57pm ET
 +0.043 / +4.31%
Today’s Change
0.46
Today|||52-Week Range
4.10
-14.05%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$29.8M

Company Description

OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company. Its develops and commercializes new cancer therapies that address treatment resistance in cancer patients. It has developed a pipeline of late-stage product candidates that are designed to block the production of specific proteins that promote treatment resistance in cancer. It's operates through three product pipeline: custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA.

Contact Information

OncoGenex Pharmaceuticals, Inc.
19820 North Creek Parkway
Bothell Washington 98011
P:(425) 686-1500
Investor Relations:
(425) 686-1514

Employees

Shareholders

Other institutional9.57%
Individual stakeholders4.85%
Mutual fund holders4.46%

Top Executives

Scott Daniel CormackPresident, CEO, Secretary, Treasurer & Director
John A. BencichChief Financial Officer & Vice President
Cindy A. JacobsChief Medical Officer & Executive Vice President
Patricia S. StewartVice President-Clinical Development
Jaime WelchVP-Marketing & Corporate Communications